Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Rectal Neoplasms 2Leukemia 2Colonic Neoplasms 2Breast Neoplasms 2Oligodendroglioma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Astrocytoma 1

Interventions

Tamoxifen 6Specimen Handling 4Neoadjuvant Therapy 3Radiotherapy 2Chemotherapy, Adjuvant 2Biopsy 2Anastrozole 2trastuzumab biosimilar HLX02 1sargramostim 1exemestane 1UAB 30 1Trastuzumab 1Surgical Procedures, Operative 1Sulindac 1Polymerase Chain Reaction 1PF-05280014 1Ontruzant 1Omacor 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Lapatinib 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Immunoenzyme Techniques 1High-Energy Shock Waves 1HER2 peptide (369-377) 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fulvestrant 1Docosahexaenoic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Intraductal, Noninfiltrating × In Situ Hybridization, Fluorescence × Clear all
NCT00671476 2014-01-10

Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

National Cancer Institute (NCI)

Phase NA Unknown
30 enrolled
Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡